复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

休市中 10-16 16:08:16

51.350

+1.200

+2.39%

最高53.350	最低50.900	成交量86.49万
今开52.000	昨收50.150	日振幅4.89%
总市值279.86亿	流通市值178.70亿	总股本5.45亿
成交额4,508万	换手率0.25%	流通股本3.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":51.35,"timestamp":1792138096008,"preClose":50.15,"halted":0,"volume":864900,"delay":0,"changeRate":0.023928215353938243,"floatShares":348000000,"shares":545000000,"eps":1.771927930791448,"marketStatus":"休市中","change":1.2,"latestTime":"10-16 16:08:16","open":52,"high":53.35,"low":50.9,"amount":45078495,"amplitude":0.048853,"askPrice":51.35,"askSize":200,"bidPrice":51.3,"bidSize":1300,"shortable":3,"etf":0,"ttmEps":1.853925570801808,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":50.15,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.5835563023580259,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2675542315","title":"生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675542315","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675542315?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:37","pubTimestamp":1792114658,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，康诺亚-B 涨9.00%，金斯瑞生物科技涨7.53%，百济神州涨5.38%，科伦博泰生物涨5.25%，再鼎医药涨4.46%，君实生物涨3.71%，泰格医药涨3.65%，复宏汉霖涨2.99%。中信建投证券表示，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993835","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","HK0000165453.HKD","09688","03347","LU0828237510.HKD","HK0000306701.USD","LU0307460666.USD","01548","HK0000320264.USD","LU1969619763.USD","BK1574","02162","161726","BK1583","HK0000320223.HKD","LU1251922891.USD","BK1515","LU2488822045.USD","LU1303224171.USD","BK1576","BK1141","LU0588546209.SGD","06990","399441","BK1500","LU1770034418.SGD","LU2328871848.SGD","01877","LU1719994722.HKD","LU0228659784.USD","02696","BK4581","HK0000306685.HKD","BK1587","KURE","BK1161","BK1588","BK4585","BK4588","LU0196878994.USD","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675358892","title":"中信证券：维持复宏汉霖(02696) “买入“评级 目标价122港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675358892","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675358892?lang=zh_cn&edition=full","pubTime":"2026-10-15 17:38","pubTimestamp":1792057131,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信证券发布研报称，生物类似药出海背景下，复宏汉霖全球价值凸显，且公司创新药第二增长曲线明确，大单品及早研管线催化丰富。该行通过DCF模型测算复宏汉霖合理股权价值为667亿港元，对应2026年目标价122港元，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1507757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674877572","title":"首席执行官朱俊增持复宏汉霖(02696.HK)2万股 每股作价49.92港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674877572","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674877572?lang=zh_cn&edition=full","pubTime":"2026-10-12 19:52","pubTimestamp":1791805958,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","02696","HK0000320264.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674188261","title":"生物医药板块继续回调 恒生生物科技指数跌2.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674188261","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674188261?lang=zh_cn&edition=full","pubTime":"2026-10-09 10:17","pubTimestamp":1791512279,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块继续回调，恒生生物科技指数跌2.31%，恒生医疗保健指数跌2.09%。个股方面，复宏汉霖（02696）跌4.84%，药明康德（02359）跌3.92%，药明合联（02268）跌3.47%，泰格医药（03347）跌3.35%，诺诚健华（09969）跌3.27%，药明生物（02269）跌3.33%，金斯瑞生物科技（01548）跌3.10%，康诺亚-B（02162）跌2.58%，百济神州（06160）跌2.44%。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","LU1688375341.USD","LU1880383366.USD","02162","01548","02696","XBI","BK1141","LU0417516738.SGD","LU1831875114.USD","LU0516422440.USD","02268","LU2488822045.USD","LU2125910500.SGD","02269","IE00B0JY6N72.USD","LU0417516902.SGD","LU2778985437.USD","LU0320764243.SGD","LU0348825331.USD","LU0181495838.USD","LU2045819591.USD","BK4588","LU0128522744.USD","HK0000320264.USD","LU0588546209.SGD","02359","LU0856984785.SGD","HK0000306685.HKD","BK1521","LU0327786744.USD","KURE","SG9999002463.SGD","BK1161","LU0463099449.HKD","LU2039709279.SGD","LU0561508036.HKD","BK1576","09969","LU1251922891.USD","SG9999014674.SGD","399441","161726","LU0359202008.SGD","03347","06160","BK4581","LU2242644610.SGD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674041881","title":"港股异动 | 复宏汉霖(02696)高开逾4% PD-L1/VEGF双抗启动一线NSCLC 2/3期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2674041881","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674041881?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:26","pubTimestamp":1791509163,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖(02696)高开逾4%。截至发稿，涨4.64%，报53.0港元，成交额4.77万港元。消息面上，10月8日，复宏汉霖在Clinicaltrials.gov网站上注册了PD-L1/VEGF双抗HLX37+化疗一线治疗晚期NSCLC的2/3期临床试验。该2/3期临床试验与K药+化疗标准疗法头对头对照，计划入组1438例受试者，预计2030年底初步完成。值得注意的是，9月23日，复宏汉霖宣布与美国生物技术公司Amberstone达成合作：以不超过400万美元的首付款，引进两款基于T-MATE™平台的条件激活型T细胞衔接器(TCE)，交易最高潜在对价约8.88亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","VXUS","HK0000165453.HKD","HK0000306701.USD","BK1161","BK4585","HK0000306685.HKD","02696","HK0000320223.HKD","BK4588","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147178188","title":"复宏汉霖更新9月股份变动月报表，H股增发14,875股","url":"https://stock-news.laohu8.com/highlight/detail?id=1147178188","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147178188?lang=zh_cn&edition=full","pubTime":"2026-10-06 17:21","pubTimestamp":1791278519,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年10月6日披露了截至2026年9月30日的股份变动月报表。公告显示，报告期内公司普通股H股的法定股本由上月末的347,862,397股增加至347,877,272股，增幅为14,875股，非上市股份稳定在197,420,456股。在2025年7月采纳的2025H股受限制股份单位计划中，9月内有92,100份受限制股份单位失效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167859940","title":"复宏汉霖（02696）公布董事会及五大专门委员会最新架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1167859940","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167859940?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:15","pubTimestamp":1790759751,"startTime":"0","endTime":"0","summary":"2026年9月30日，上海复宏汉霖生物技术股份有限公司发布公告，披露公司董事会成员及其在各专门委员会中的最新任职情况。现任董事会共9名成员，具体构成为：1名执行董事、5名非执行董事及3名独立非执行董事。公司表示，此次披露旨在进一步强化公司治理结构，明确董事会及下设委员会的职责分工，以提升决策效率和治理透明度。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136298642","title":"复宏汉霖公布董事会人事调整 两名董事辞任、三项新任命落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1136298642","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136298642?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:15","pubTimestamp":1790759729,"startTime":"0","endTime":"0","summary":"2026年9月30日，复宏汉霖发布公告称，公司董事会收到两名董事辞任及多项人事任命，涉及董事会主席更替、非执行董事及独立非执行董事提名等事项。\\n\\n截至公告披露日，复宏汉霖董事会成员包括：主席兼非执行董事Xingli Wang博士，执行董事朱俊博士，非执行董事陈启宇先生、陈玉卿先生、关晓晖女士、刘毅博士，以及独立非执行董事苏德扬先生、陈力元博士、宋瑞霖博士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671762772","title":"港股异动 | 复宏汉霖(02696)涨近6% 公司核心管线价值持续验证 H药将首次公布美国患者数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2671762772","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671762772?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:26","pubTimestamp":1790753181,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨近6%，截至发稿，涨5.83%，报58.95港元，成交额4162.21万港元。消息面上，2026年欧洲肿瘤内科学会年会将于10月23日至27日在西班牙马德里举行。本届大会期间，复宏汉霖将公布12项研究数据，覆盖抗PD-1单抗H药 汉斯状、PD-L1 ADC HLX43及创新小分子CDK4/6抑制剂复妥宁等核心肿瘤管线产品，聚焦肺癌、消化道肿瘤及乳腺癌等高发癌种的最新进展与概念验证成果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320223.HKD","KCAI","HK0000306701.USD","BK4585","HK0000320264.USD","VXUS","02696","BK4588","BK1161","HK0000306685.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671260330","title":"复宏汉霖盘中涨超5% 汉斯状®两项消化道肿瘤领域研究亮相ASTRO2026年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2671260330","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671260330?lang=zh_cn&edition=full","pubTime":"2026-09-29 11:41","pubTimestamp":1790653260,"startTime":"0","endTime":"0","summary":"模拟交易客户端复宏汉霖盘中涨超5%，截至发稿，股价上涨2.28%，现报56.05港元，成交额1533.69万港元。据复宏汉霖官微消息，在美国放射肿瘤学会年会上，复宏汉霖自主研发的创新型抗PD-1单抗H药汉斯状两项消化道肿瘤领域研究以壁报形式发布结果。在本次ASTRO大会上发布的TORCH-C研究是一项随机II期临床试验，针对MSS/pMMR型高危局部晚期结肠癌，评估了新辅助短程放疗联合CAPOX方案及斯鲁利单抗的疗效和安全性。此前该研究数据已于2026年美国临床肿瘤学会年会上发布。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-29/doc-initnfqm3022152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306685.HKD","HK0000320264.USD","02696","HK0000306701.USD","HK0000320223.HKD","HK0000165453.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671262206","title":"港股异动 | 复宏汉霖(02696.HK)盘中涨超5% 汉斯状®两项消化道肿瘤领域研究亮相ASTRO 2026年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2671262206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671262206?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:50","pubTimestamp":1790650220,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000320223.HKD","02696","HK0000320264.USD","BK1161","HK0000306701.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119311542","title":"复宏汉霖2026年中期营收35.88亿元，经调整净利润5.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119311542","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119311542?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:07","pubTimestamp":1790240836,"startTime":"0","endTime":"0","summary":"2026年上半年，复宏汉霖实现营业收入35.88亿元，同比增长27.3%。经调整的净利润为5.72亿元，较上年同期的3.90亿元增长46.7%。公司同期间经营活动现金流约为5.59亿元，同比降低27.4%。报告期内，研发开支约14.51亿元，较上年同期的9.95亿元增长约45.7%，占总营收比重超过四成。管理费用支出约2.48亿元，较上年同期的1.85亿元增长约34%。业务分项上，主要核心产品销售收入增长稳健，其中曲妥珠单抗产品报告期销售额约14.73亿元，叠加许可收入约0.11亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复宏汉霖2026年中期营收35.88亿元，经调整净利润5.72亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 |  港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2399975544.HKD","LU0348825331.USD","LU0828237510.HKD","BK1141","LU0516422366.SGD","06160","02162","09926","BK1583","02696","06990","02268","01877","02269","09688","LU1242518857.USD","LU0456846285.SGD","LU0561508036.HKD","LU1961090484.USD","09969","LU0348783233.USD","KURE","LU0540923850.HKD","LU2328871848.SGD","SG9999002463.SGD","BK1515","XBI","LU0348766576.USD","LU1880383366.USD","161726","399441","LU0516423174.USD","03347","SG9999014674.SGD","LU1770034418.SGD","01548","BK4581","09995","LU1719994722.HKD","LU1242518931.SGD","HK0000306701.USD","LU2039709279.SGD","BK1576","LU0140636845.USD","LU1303224171.USD","SG9999002562.SGD","LU3063872942.SGD","688428","LU0856984785.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122980175","title":"复宏汉霖与Amberstone签署T细胞衔接器全球合作协议 最高对价逾6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122980175","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122980175?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:02","pubTimestamp":1790154121,"startTime":"0","endTime":"0","summary":"2026年9月23日，上海复宏汉霖生物技术股份有限公司发布自愿性公告称，公司已与Amberstone Biosciences, Inc.签订合作及许可协议，就两款T细胞衔接器产品在全球范围内的研究、开发、生产及商业化展开合作。PCC确定后，复宏汉霖将负责后续的研究、开发、生产及商业化工作。\\n\\n复宏汉霖在公告中提醒，药物研发具有较高的不确定性，合作产品能否最终成功商业化尚存风险，投资者需审慎决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669589101","title":"复宏汉霖(02696)就两款T细胞衔接器产品与Amberstone订立的合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2669589101","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669589101?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:00","pubTimestamp":1790154031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，于2026年9月23日，公司与Amberstone Biosciences, Inc.订立一份合作及许可协议，据此，双方同意基于Amberstone专有的T-MATE 技术平台，就两款T细胞衔接器产品用于所有人类用途的全球范围内的研究、开发、生产及商业化作出约定。本次合作有望基于双方在相关领域技术优势和研发能力，共同推进合作产品的研究与开发，有助于进一步丰富公司的创新产品管线，提升公司的持续创新能力和市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","HK0000320223.HKD","02696","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669935109","title":"复星医药：复宏汉霖获Amberstone授予独家许可，协议包含至多2.36亿美元的总付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2669935109","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669935109?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:38","pubTimestamp":1790152732,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02696","600196","BK1515","BK0183","BK0060","BK0096","HK0000165453.HKD","02196","BK0187","HK0000320264.USD","BK0239","HK0000306685.HKD","BK0175","BK0188","BK1161","HK0000306701.USD","BK0028","BK1593","BK1191","BK0196","BK0012","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","09969","01877","09995","02359","01548","02696","02162","06990","03347","02269","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669367441","title":"港股异动 | 复宏汉霖(02696)早盘涨超8% 汉达远®于巴基斯坦获批 近期获纳入国家基本药物目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2669367441","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669367441?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:54","pubTimestamp":1789955650,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖早盘涨超8%，截至发稿，涨8.56%，报64.8港元，成交额2010.27万港元。消息面上，近日，据复宏汉霖官微消息，公司宣布，公司商业合作伙伴Getz Pharma  Limited收到相关注册证书，复宏汉霖自主开发和生产的汉达远获得巴基斯坦药监局批准上市，商品名为Adaliget，获批原研阿达木单抗在当地的所有适应症。汉达远已于2026年7月被纳入中国《国家基本药物目录》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","HK0000306685.HKD","KCAI","HK0000320223.HKD","02696","HK0000320264.USD","BK4585","BK1161","HK0000306701.USD","HK0000165453.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","LU0561508036.HKD","LU0540923850.HKD","LU0327786744.USD","LU0979878070.USD","LU0348767384.USD","09969","LU0348766576.USD","LU0634319403.HKD","LU2045819591.USD","01548","02696","BK1515","LU1961090484.USD","399441","BK1588","02162","02359","LU0516422952.EUR","06160","LU0348784397.USD","BK4588","LU1880383366.USD","BK1610","02269","LU0128522744.USD","LU0029874905.USD","LU0196878994.USD","09995","HK0000165453.HKD","LU2488822045.USD","LU0320764243.SGD","LU0320764599.SGD","01877","LU0463099449.HKD","161726","LU1303224171.USD","LU0456827905.SGD","LU2242644610.SGD","XBI","KURE","LU1188198961.HKD","LU0244354667.USD","06990","09926","LU0326950275.SGD","LU0052750758.USD","03347","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641935","title":"调仓提示！华宝基金港股通创新药ETF（520880）成份股“5进3出”，复宏汉霖等多只新入通标的获纳入","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641935","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667641935?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:10","pubTimestamp":1789470600,"startTime":"0","endTime":"0","summary":"9月14日，100%布局创新药研发龙头的恒生港股通创新药精选指数季度调整正式生效，被动跟踪该指数的港股通创新药ETF华宝同步调仓换血。成份股“5进3出”，总数回升至50只。港股通创新药ETF华宝标的指数相较同类指数率先导入“新鲜血液”：此次调入的5只成份股中，复宏汉霖、和铂医药-B、基石药业-B、瑞博生物-B等4只均为9月7日新纳入港股通的标的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-15/doc-inirxhzq8479614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","HK0000165453.HKD","HK0000320223.HKD","159316","FLHK","HK0000306701.USD","HK0000320264.USD","HK0000306685.HKD","02696","520880"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0118},{"period":"1month","weight":-0.1046},{"period":"3month","weight":-0.1108},{"period":"6month","weight":-0.3919},{"period":"1year","weight":-0.2985},{"period":"ytd","weight":-0.0999}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.085211},{"month":7,"riseRate":0.428571,"avgChangeRate":0.040127},{"month":8,"riseRate":0.571429,"avgChangeRate":0.005816},{"month":9,"riseRate":0,"avgChangeRate":-0.125139},{"month":10,"riseRate":0.25,"avgChangeRate":-0.037894},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}